A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

NCT ID: NCT05901519

Last Updated: 2025-03-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-16
• Study Completion Date: 2026-08-31

Brief Summary

Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients treated with Prednisone

Prednisone will be administered for three days before starting RT, and during the first three fractions of RT. Following an interim analysis of the decrease in sTNFR1 level, a decision will be made whether to administer prednisone for seven days prior to RT, and to continue for additional seven days during RT.

Group Type: EXPERIMENTAL

Prednisone

Intervention Type: DRUG

Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day

Interventions

Prednisone

Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with hepatocellular carcinoma are eligible for this trial. Hepatocellular carcinoma is defined as having at least one of the following:

1. Biopsy proven hepatocellular carcinoma (HCC); or

2. A discrete hepatic tumor(s) as defined by the AASLD criteria (80) - for cirrhotic patients, >1cm with arterial hypervascularity and venous or delayed phase washout on contrast enhanced CT or MRI.

• Patients must have recovered from the acute effects of prior liver-directed therapy (e.g., RT, RFA, or TACE), and a minimum of 4 weeks must have passed since the last procedure and protocol therapy.
• Patients must have a performance status of ≤2.
• Patients must be 18 years of age or older.
• Patients with at least one of the following:

1. ALBI score equal to (-1.81) or higher (worse). This value was calculated as the equivalent ALBI score for CP score equal 7 in Cousins et al study's cohort(59).

2. Lesion(s) with a cumulative treatment diameter of ≥ 4cm.

3. CP score equal to 7 or higher (worse).

• Patients must understand and be willing to sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.

Exclusion Criteria

• Any serious disease, comorbidity or intercurrent illness which precludes delivery of radiation therapy, as determined by the treating investigator.
• Any contraindication to the administration of steroids, including

• Documented hypersensitivity to prednisone or any component of the formulation.
• Systemic fungal infection.
• Patients with uncontrolled infections or with chronic infections requiring antibiotics.

Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.

• Uncontrolled hyperglycemia.

• Patients with insulin -dependent diabetes.
• Patients with decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage.
• Active gastrointestinal bleeding within 30 days of enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Michigan Rogel Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Theodore Lawrence

Role: PRINCIPAL_INVESTIGATOR

University of Michigan Rogel Cancer Center

Locations

Rogel Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Theodore Lawrence

Role: CONTACT

tsl@med.umich.edu

7346479955

Facility Contacts

Theodore Lawrence, M.D., Ph.D.

Role: primary

Other Identifiers

HUM00234029

Identifier Type: OTHER

Identifier Source: secondary_id

UMCC 2022.120

Identifier Type: -

Identifier Source: org_study_id